Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has faltered in a reminder of the approach’s struggles as a standalone therapy.
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
Post navigation
Next Post
From Images to Data 